Anthonie van der Wekken

Search results

• 2021

  Detection of on-target ALK inhibitor resistance mutations and treatment options for patients with non-small cell lung cancer

  UMCG Mol Tumor Board, Koopman, B., Groen, H. J. M., Schuuring, E., Timens, W., van Kempen, L. & Van der Wekken, A. J., Aug-2021, In: Virchows Archiv. 479, SUPPL 1, p. S59-S60 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2020

  Clinical value of EGFR gene amplifications detected using amplicon based targeted next generation sequencing data in lung adenocarcinoma patients

  Meng, P., Wei, J., Terpstra, M. M., van Rijk, A., Tamminga, M., Scherpen, F., ter Elst, A., Alimohamed, M. Z., Johansson, L. F., Hiltermann, T. J. N., Groen, H. J., Kok, K., van der Wekken, A. J. & van den Berg, A., Aug-2020, In: Cancer Research. 80, 16, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer

  Gijtenbeek, R. G. P., Damhuis, R. A. M., Groen, H. J. M., Van der Wekken, A. J. & Van Geffen, W. H., 7-Sep-2020, In: European Respiratory Journal. 56, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

  Meng, P., Koopman, B., Kok, K., ter Elst, A., Schuuring, E., van Kempen, L. C., Timens, W., Hiltermann, T. J. N., Groen, H. J. M., van den Berg, A. & van der Wekken, A. J., Sep-2020, In: Annals of Oncology. 31, p. S1106-S1106 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2019

  An all-in-one transcriptome-based assay to identify therapy-related biomarkers in lung cancer

  Kok, K., Wei, J., Rybczynska, A. A., Meng, P., Terpstra, M. M., van der Wekken, A. J., Hiltermann, J. T., Schuuring, E., Groen, H. J. & van den Berg, A., Jul-2019, In: Cancer Research. 79, 13, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• ctDNA a promising predictive marker for treatment with PD-1 inhibitors in KRAS mutated NSCLC after platinum based chemotherapy

  Hiltermann, T. J. N., Hijmering-Kappelle, L. B. M., Azpurua, M. L. A., van der Wekken, A. J., Hiddinga, B. L., Timens, W., Groen, H. J. M. & Schuuring, E., Jul-2019, In: Cancer Research. 79, 13, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Detecting therapy-guiding aberrations in platelets and plasma at the transcriptome level in non-small-cell lung cancer

  Meng, P., Rybczynska, A. A., Wei, J., Terpstra, M. M., Timens, W., Schuuring, E., Hiltermann, T. J. N., Groen, H. J. M., Kok, K., Van der Wekken, A. J. & Van den Berg, A., Nov-2019, In: Annals of Oncology. 30, 1 p., UNSP mdz413.025.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Modeling of drug-protein interactions to support clinical decision making for therapy-resistant EGFR or ALK-positive non-small cell lung carcinoma

  Santos, J. F. V. M. R., Hiddinga, B. I., van Kempen, L. C., ter Elst, A., Hijmering, L. B., Hiltermann, T. J., Schuuring, E., Groves, M. R., Groen, H. J. & van der Wekken, A. J., Jul-2019, In: Cancer Research. 79, 13, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• PD-L1 expression, CD8 cells and MHC-class-1 Beta-2-microglobulin expression in advanced non-small lung cancer

  Hijmering-Kappelle, L., Hiltermann, J., Hiddinga, B., van der Wekken, A., 't Hart, N., Groen, H. & Timens, W., Jul-2019, In: Cancer Research. 79, 13, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2018

  Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer

  van Veggel, B., van der Wekken, A., Hashemi, S., Cornelissen, R., Monkhorst, K., Heideman, D., Radonic, T., Smit, E. F., Schuuring, E. & De Langen, J., Oct-2018, In: Annals of Oncology. 29, Suppl.8, p. viii524-viii525 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Urine cell-free DNA as early biomarker in immunotherapy response in NSCLC

  van der Wekken, A. J., ter Elst, A., Miedema, A., Hiltermann, T. J., Goen, H. J. & Schuuring, E., Jul-2018, In: Cancer Research. 78, 13, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2017

  A comprehensive RNA-based assay for treatment prediction in non-small cell lung cancer patients

  Kok, K., Wei, J., Rybczynska, A., Terpstra, M., van der Wekken, A., Hilterman, J., Schuuring, E., Sijmons, R., Groen, H. & van den Berg, A., Jul-2017, In: Cancer Research. 77, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• All-in-one RNA-based assay to detect therapeutic biomarkers in lung cancer

  Wei, J., Rybczynska, A., van der Wekken, A., Saber, A., Terpstra, M., Schuuring, E., Timens, W., Hiltermann, T., Groen, H., van den Berg, A. & Kok, K., Oct-2017, In: Annals of Oncology. 28, 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• First-in-human PET imaging with the PD-L1 antibody Zr-89-atezolizumab

  Bensch, F., van der Veen, E., Jorritsma, A., Lub-de Hooge, M., Boellaard, R., Oosting, S., Schröder, C., Hiltermann, J., van der Wekken, A., Groen, H., Fine, B., McKnight, N., Bohorquez, S. S., Williams, S., Veronese, L., Mancao, C., Brouwers, A. H. & de Vries, E., Jul-2017, In: Cancer Research. 77, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Molecular Tumor Board treatment predictions on rare EGFR exon 20 mutations

  van der Wekken, A. J., Groves, M. R., ter Elst, A., 't Hart, N. A., Hijmering-Kappelle, L. B., Hiltermann, T. J., van den Berg, A., Timens, W., Schuuring, E. & Groen, H. J., Jul-2017, In: Cancer Research. 77, 2 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Treatment decision-making of rare ERBB2 (HER2) mutations in lung cancer; a role for multidisciplinary molecular tumor boards: A role for multidisciplinary molecular tumor boards

  ter Elst, A., 't Hart, N. A., van der Wekken, A. J., Timens, W., Hijmering-Kappelle, L. B., Hospers, G. A., Jalving, H., van der Logt, E. M., van Kempen, L. C., Oosting, S. F., Groves, M. R., Hiltermann, T. J., van den Berg, A., Groen, H. J. & Schuuring, E., Jul-2017, In: Cancer Research. 77, 2 p., Abstract 754.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2016

  The efficacy and safety of CT-guided percutaneous hookwire localization in VATS for pulmonary nodules

  Klinkenberg, T., Dinjens, L., Rienhart, W., van der Wekken, A. J., Groen, H. J. M., Timens, W., Van De Wauwer, C., de Bock, G. H., Mariani, M. & van Geffen, W., 1-Sep-2016, In: European Respiratory Journal. 48, 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2015

  Comparison of Different ALK Tests in Non-Small Cell Lung Cancer (NSCLC) Patients before and after Crizotinib and Their Clinical Outcome

  van der Wekken, A. J., Hart, N. T., Hiltermann, T., Timens, W., Groen, H. J. & Schuuring, E., Sep-2015, In: Journal of Thoracic Oncology. 10, 9, p. S378-S378 1 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Comparison of different ALK tests in non-small cell lung cancer (NSCLC) patients treated with crizotinib and their clinical outcome

  Wekken, van der, A. J., Hiltermann, T. J. N., Timens, W., Schuuring, E. & Groen, H. J. M., 1-Aug-2015, In: Cancer Research. 75, 3 p.

  Research output: Contribution to journal › Meeting Abstract › Academic

• Detection of fusion genes in lung cancer biopsies of crizotinib resistant patients

  Saber, A., van der Wekken, A., Kok, K., Terpstra, M. M., Mastik, M. F., Timens, W., Schuuring, E. M. D., Hiltermann, T. J., Groen, H. J. M. & van den Berg, A., 1-Aug-2015, In: Cancer Research. 75, 3 p.

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2013

  Pre-treatment EGFR mutation analysis predicts clinical outcome in a retrospective analysis of 24 non-squamous non-small-cell lung cancer (NSCLC) patients treated with second line afatinib.

  Wekken, van der, A. J., Kuiper, J. L., Heideman, D. A. M., Schuuring, E., Timens, W., Thunnissen, E., Groen, H. J. M. & Smit, E. F., 15-Apr-2013, In: Cancer Research. 73, 8, p. 3526

  Research output: Contribution to journal › Meeting Abstract › Academic